

Publications by PaCCSC Members

2017

1. Agar MR, Draper B, Caplan GA. Neuroleptics for Delirium: More Research is Needed-Reply. *JAMA Intern Med.* 2017 Jul 1;177(7):1055-1056.
2. Johnson MJ, Currow DC. Unmasking chronic breathlessness. *Curr Opin Support Palliat Care.* 2017 Jun 28. [Epub ahead of print]
3. Ahmadi Z, Currow DC, Ekström M. Palliative oxygen for chronic breathlessness: what new evidence? *Curr Opin Support Palliat Care.* 2017 Jul 20. [Epub ahead of print]
4. Currow DC, Skipworth RJ. The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia. *Future Oncol.* 2017 Jun 16. [Epub ahead of print]
5. To THM, LeBlanc TW, Eastman P, Neoh K, Agar MR, To LB, Rowett D, Vandersman Z, Currow DC. The Prospective Evaluation of the Net Effect of Red Blood Cell Transfusions in Routine Provision of Palliative Care. *J Palliat Med.* 2017 Jun 9. [Epub ahead of print]
6. Smallwood N, Gaffney N, Gorelik A, Irving L, Le B, Philip J. Junior doctors' attitudes to opioids for refractory breathlessness in patients with advanced chronic obstructive pulmonary disease. *Intern Med J.* 2017 Jun 6. [Epub ahead of print]
7. Philip J, Crawford G, Brand C, Gold M, Miller B, Hudson P, Smallwood N, Lau R, Sundararajan V. A conceptual model: Redesigning how we provide palliative care for patients with chronic obstructive pulmonary disease. *Palliat Support Care.* 2017 May 31:1-9. [Epub ahead of print]
8. Johnson MJ, Yorke J, Hansen-Flaschen J, Lansing R, Ekström M, Similowski T, Currow DC. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. *Eur Respir J.* 2017 May 25;49(5). pii: 1602277. Print 2017 May.
9. Hussain JA, Bland M, Langan D, Johnson MJ, Currow DC, White IR. Quality of missing data reporting and handling in palliative care trials demonstrates that further development of the CONSORT statement is required: a systematic review. *Clin Epidemiol.* 2017 May 19. [Epub ahead of print]
10. Johnson MJ, Ekstrom M, Currow DC. In response to C Walshe, 'The state of play'. *Palliat Med.* 2017 May 1 [Epub ahead of print]
11. Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia. *Ann Oncol.* 2017 May 4. [Epub ahead of print]
12. Ekström M, Bajwah S, Bland JM, Currow DC, Hussain J, Johnson MJ. One evidence base; three stories: do opioids relieve chronic breathlessness? *Thorax.* 2017 Apr 4. pii: thoraxjnl-2016-209868. [Epub ahead of print]
13. Currow DC, Dal Grande E, Ferreira D, Johnson MJ, McCaffrey N, Ekström M. Chronic breathlessness associated with poorer physical and mental health-related quality of life (SF-12) across all adult age groups. *Thorax.* 2017 Mar 29. pii: thoraxjnl-2016-209908. [Epub ahead of print]
14. Barbetta C, Currow DC, Johnson MJ. Non-opioid medications for the relief of chronic breathlessness: current evidence. *Expert Rev Respir Med.* 2017 Apr;11(4):333-341. Epub 2017 Mar 17.

15. Bush SH, Marchington KL, Agar M, Davis DH, Sikora L, Tsang TW. Quality of clinical practice guidelines in delirium: a systematic appraisal. *BMJ Open*. 2017 Mar 10;7(3):e013809.
16. Agar MR, Lawlor PG, Quinn S, Draper B, Caplan GA, Rowett D, Sanderson C, Hardy J, Le B, Eckermann S, McCaffrey N, Devilee L, Fazekas B, Hill M, Currow DC. Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial. *JAMA Intern Med*. 2017 Jan 1;177(1):34-42
17. Collier A, Breaden K, Phillips JL, Agar M, Litster C, Currow DC. Caregivers' Perspectives on the Use of Long-Term Oxygen Therapy for the Treatment of Refractory Breathlessness: A Qualitative Study. *J Pain Symptom Manage*. 2017 Jan;53(1):33-39

2016

18. Currow DC, Abernethy AP, Fallon M, Portenoy RK. Repurposing Medications for Hospice/Palliative Care Symptom Control Is No Longer Sufficient: A Manifesto for Change. *J Pain Symptom Manage*. 2016 Dec 30.
19. Clark K, Connolly A, Clapham S, Quinsey K, Eagar K, Currow DC. Physical Symptoms at the Time of Dying Was Diagnosed: A Consecutive Cohort Study To Describe the Prevalence and Intensity of Problems Experienced by Imminently Dying Palliative Care Patients by Diagnosis and Place of Care. *J Palliat Med*. 2016 Dec;19(12):1288-1295.
20. Watts GJ, Clark K, Agar M, Davidson PM, McDonald C, Lam LT, Sajkov D, McCaffrey N, Doogue M, Abernethy AP, Currow DC; Australian national Palliative Care Clinical Studies Collaborative (PaCCSC). Study protocol: a phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo-controlled trial investigating the clinical effect and cost-effectiveness of sertraline for the palliative relief of breathlessness in people with chronic breathlessness. *BMJ Open*. 2016 Nov 29;6(11)
21. Agar MR, Quinn SJ, Crawford GB, Ritchie CS, Phillips JL, Collier A, Currow DC. Predictors of Mortality for Delirium in Palliative Care. *J Palliat Med*. 2016 Nov;19(11):1205-1209.
22. Currow DC, Davidson PM, Higginson IJ. "Outcomes" Is Not an Oxymoron in Hospice/Palliative Care. *J Palliat Med*. 2016 Nov;19(11):1128-1129
23. Ekström M, Ahmadi Z, Bornefalk-Hermansson A, Abernethy A, Currow D. Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. *Cochrane Database Syst Rev*. 2016 Nov 25;11:
24. Hosie A, Agar M, Phillips J. Re-thinking our approach to care of the dying person with delirium: time for a new care paradigm. *Int J Palliat Nurs*. 2016 Oct 2;22(10):472-473.
25. Clark K, Lam LT, Talley NJ, Phillips JL, Currow DC. Identifying Factors That Predict Worse Constipation Symptoms in Palliative Care Patients: A Secondary Analysis. *J Palliat Med*. 2016 Oct 18
26. Ahmadi Z, Bernelid E, Currow DC, Ekström M. Prescription of opioids for breathlessness in end-stage COPD: a national population-based study. *Int J Chron Obstruct Pulmon Dis*. 2016 Oct 21;11:2651-2657.
27. Currow DC, Phillips J, Clark K. Using opioids in general practice for chronic non-cancer pain: an overview of current evidence. *Med J Aust*. 2016 Oct 3;205(7):334-5.
28. Clark K, Eagar K, Currow DC. Embedding Objective Measurements of Quality into Routine Practice in Hospice/Palliative Care. *J Pain Symptom Manage*. 2016 Sep;52(3):e5-7.
29. McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms. *Health Qual Life Outcomes*. 2016 Sep 20;14(1):133.
30. Currow DC, Johnson MJ. Chronic breathlessness: silent and deadly. *Curr Opin Support Palliat Care*. 2016 Sep;10(3):221-2.
31. Luckett T, Phillips J, Lovell M, Lintzeris N, Martin J, Allsop D, McGregor I, Solowij N, Phillips J, Lee J, Aggarwal R, Chye R, Sheehan C, Currow D, McCaffrey N, Agar M, 'Clinical trials of

- medicinal cannabis for symptoms from advanced cancer: A survey of potential participants' preferences, attitudes and beliefs', *Internal Medicine Journal* accepted for publication 6 Aug 2016
32. Bush SH, Lacaze-Masmonteil N, McNamara-Kilian MT, MacDonald AR, Tierney S, Momoli F, Agar M, Currow DC, Lawlor PG. The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial. *Trials*. 2016 Aug 11;17:399
 33. McCaffrey N, Al-Janabi H, Currow D, Hoefman R, Ratcliffe J, 'Protocol for a systematic review of preference-based instruments for measuring care-related outcomes and their suitability for the palliative care setting', *BMJ Open* accepted for publication 20th July 2016
 34. Agar MR, Quinn SJ, Crawford GB, Ritchie CS, Phillips JL, Collier A, Currow DC. Delirium heralds revised prognosis in palliative care. *J Palliat Med* 2015 [Epub ahead of print 2016 June 16]
 35. Clark K, Lam LT, Talley NJ, Quinn J, Blight A, Byfieldt N, Currow DC. Assessing the Presence and Severity of Constipation with Plain Radiographs in Constipated Palliative Care Patients. *J Palliat Med*. 2016 Jun;19(6):617-21.
 36. McCaffrey N, Bradley S, Ratcliffe J, Currow D 2016. 'What aspects of quality of life are important from palliative care patients' perspectives?' *Journal of Pain & Symptom Management*; DOI: 10.1016/j.jpainsymman.2016.02.012. [Epub ahead of print]
 37. Currow DC, Phillips J, Clark K. Using opioids in general practice for chronic non-cancer pain: an overview of current evidence. *Med J Aust*. 2016 May 2;204(8):305-9.
 38. Ekström M, Johnson MJ, Kaasa S, Jensen M, Schiöler L, Currow DC. Who experiences higher and increasing breathlessness in advanced cancer? The longitudinal EPCC Study. *Supp Care Cancer* 2016 [Epub ahead of print 2016 Apr 9]
 39. McCaffrey, N., et al., How Accurately Do Consecutive Cohort Audits Predict Phase III Multisite Clinical Trial Recruitment in Palliative Care? *J Pain Symptom Manage*, 2016. 51(4): p. 748-55.
 40. Nikles J, Mitchell GK, Hardy J, Senior H, Carmont SA, Schluter PJ, Vora R, Currow D, Yelland M. Single-patient multiple crossover studies to determine the effectiveness of paracetamol in relieving pain suffered by patients with advanced cancer taking regular opioids: A pilot study. *Palliat Med* 2016. [Epub ahead of print 2016 Mar 1]
 41. Martins, R.T., et al., Effects of low-dose morphine on perceived sleep quality in patients with refractory breathlessness: A hypothesis generating study. *Respirology*, 2016. 21(2): p. 386-91.
 42. To, THM., To LB, Currow DC, Can we detect transfusion benefits in palliative care patients?
 43. Landers, A., W. Muircroft, and H. Brown, Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer. *BMJ Support Palliat Care*, 2016. 6(1): p. 75-9.
 44. Muircroft, M, D Currow, Palliative Care in Advanced Pancreatic Cancer. *Cancer Forum*, 2016. Volume 40 Number 1
 45. Johnson, M.J. and D.C. Currow, How much evidence isn't in evidence-based guidelines? *Ann Oncol*, 2016. 27(1): p. 205.
 46. Johnson, M.J. and D.C. Currow, Minimal clinically important difference and Edmonton Symptom Assessment Scale. *Cancer*, 2016. 122(1): p. 158-9.
 47. Johnson, M.J. and D.C. Currow, Treating breathlessness in lung cancer patients: the potential of breathing training. *Expert Rev Respir Med*, 2016.
 48. Johnson, M.J., et al., A Mixed-Methods, Randomized, Controlled Feasibility Trial to Inform the Design of a Phase III Trial to Test the Effect of the Handheld Fan on Physical Activity and Carer Anxiety in Patients With Refractory Breathlessness. *J Pain Symptom Manage*, 2016. 51(5): p. 807-15.
 49. Johnson, M.J., et al., Breathlessness in Elderly Adults During the Last Year of Life Sufficient to Restrict Activity: Prevalence, Pattern, and Associated Factors. *J Am Geriatr Soc*, 2016. 64(1): p. 73-80.

50. Hatano Y, Moroni M, Wilcock A, Quinn S, Csikós Á, Allan SG, Agar M, Clark K, Clayton JM, Currow DC. Pharmacovigilance in hospice/palliative care: the net immediate and short-term effects of dexamethasone for anorexia. *BMJ Support Palliat Care*, 2016.
51. Ferreira, D.H., et al., Blinded Patient Preference for Morphine Compared to Placebo in the Setting of Chronic Refractory Breathlessness-An Exploratory Study. *J Pain Symptom Manage*, 2016. 51(2): p. 247-54.
52. Disalvo D, Lockett T, Agar M, Bennett A, Davidson PM. Systems to identify potentially inappropriate prescribing in people with advanced dementia: a systematic review. *BMC Geriatr*. 2016 May 31;16:114.
53. Lockett T, Disler R, Hosie A, Johnson M, Davidson P, Currow D, Sumah A, Phillips J. Content and quality of websites supporting self-management of chronic breathlessness in advanced illness: a systematic review. *NPJ Prim Care Respir Med*. 2016 May 26;26:16025.
54. Ekstrom, M., et al., Breathlessness During the Last Week of Life in Palliative Care: An Australian Prospective, Longitudinal Study. *J Pain Symptom Manage*, 2016.
55. Sanderson C, Quinn SJ, Agar M, Chye R, Clark K, Doogue M, Fazekas B, Lee J, Lovell MR, Rowett D, Spruyt O, Currow DC. Pharmacovigilance in hospice/palliative care: net effect of pregabalin for neuropathic pain. *BMJ Support Palliat Care* 2016 [Epub ahead of print 2016 Feb 23]
56. Currow, D.C., et al., The need to research refractory breathlessness. *Eur Respir J*, 2016. 47(1): p. 342-3.

2015

58. Agar MR, Delirium heralds revised prognosis in palliative care. *J Palliat Med* 2015 [Epub ahead of print 2016 June 16]
59. Uronis, H.E., et al., Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis. *Thorax*, 2015. 70(5): p. 492-4.
60. Smallwood, N., et al., Management of refractory breathlessness with morphine in patients with chronic obstructive pulmonary disease. *Intern Med J*, 2015. 45(9): p. 898-904.
19. Sanderson, C., et al., Pharmacovigilance in hospice/palliative care: net effect of gabapentin for neuropathic pain. *BMJ Support Palliat Care*, 2015. 5(3): p. 273-80.
20. Phillips, J., et al., A population-based cross-sectional study that defined normative population data for the life-space mobility assessment-composite score. *J Pain Symptom Manage*, 2015. 49(5): p. 885-93.
21. Nikles, J., et al., Testing pilocarpine drops for dry mouth in advanced cancer using n-of-1 trials: A feasibility study. *Palliat Med*, 2015.
22. Morgan, N.A., D. Rowett, and D.C. Currow, Analysis of drug interactions at the end of life. *BMJ Support Palliat Care*, 2015.
23. McCaffrey, N., et al., Potential economic impact on hospitalisations of the Palliative Care Clinical Studies Collaborative (PaCCSC) ketamine randomised controlled trial. *Aust Health Rev*, 2015.
24. McCaffrey, N. and D.C. Currow, Separated at birth? *BMJ Support Palliat Care*, 2015. 5(1): p. 2-3.
25. McCaffrey, N., J.B. Cassel, and J. Coast, Bringing the economic cost of informal caregiving into focus. *Palliat Med*, 2015. 29(10): p. 866-7.
26. McCaffrey, N., et al., Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space. *PLoS One*, 2015. 10(3): p. e0115544.
27. LeBlanc, T.W., et al., Polypharmacy in patients with advanced cancer and the role of medication discontinuation. *Lancet Oncol*, 2015. 16(7): p. e333-41.
28. Kutner, J.S., et al., Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. *JAMA Intern Med*, 2015. 175(5): p. 691-700.
29. Johnson, M.J. and D.C. Currow, Re: Hui et al., which treatment is better? *J Pain Symptom*

- Manage, 2015. 49(4): p. e6-7.
30. Johnson, M.J. and D.C. Currow, Chronic refractory breathlessness is a distinct clinical syndrome. *Curr Opin Support Palliat Care*, 2015. 9(3): p. 203-5.
 31. Johnson, M.J. and D.C. Currow, Minimal clinically important difference and Edmonton Symptom Assessment Scale. *Cancer*, 2015.
 32. Hussain, J.A., et al., Missing data in randomized controlled trials testing palliative interventions pose a significant risk of bias and loss of power: a systematic review and meta-analyses. *J Clin Epidemiol*, 2015.
 33. Ekstrom, M.P., A.P. Abernethy, and D.C. Currow, The management of chronic breathlessness in patients with advanced and terminal illness. *BMJ*, 2015. 349: p. g7617.
 34. Ekstrom, M., et al., Effects of Opioids on Breathlessness and Exercise Capacity in Chronic Obstructive Pulmonary Disease: A Systematic Review. *Ann Am Thorac Soc*, 2015.
 35. Ekstrom, M., D.C. Currow, and M.J. Johnson, Outcome measurement of refractory breathlessness: endpoints and important differences. *Curr Opin Support Palliat Care*, 2015. 9(3): p. 238-43.
 36. Ekstrom, M., et al., Low-dose opioids should be considered for symptom relief also in advanced chronic obstructive pulmonary disease (COPD). *Evid Based Med*, 2015. 20(1): p. 39.
 37. Currow, D.C., M.T. Vergo, and M. Ekstrom, Sudden Death in Palliative Care. *J Pain Symptom Manage*, 2015. 50(3): p. e1-2.
 38. Currow, D.C., et al., Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors? *BMJ Open*, 2015. 5(5): p. e006818.
 39. Currow, D.C., et al., Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. *J Pain Symptom Manage*, 2015. 49(5): p. 814-21.
 40. Currow, D.C. and M.J. Johnson, Distilling the essence of breathlessness: the first vital symptom. *Eur Respir J*, 2015. 45(6): p. 1526-8.
 41. Currow, D.C., A. Hutchinson, and M.J. Johnson, Re: Asia, Australia and New Zealand Dyspnoea in Emergency Departments (AANZDEM) study: Rationale, design and analysis. *Emerg Med Australas*, 2015. 27(5): p. 498-9.
 42. Currow, D.C. and I.J. Higginson, Cochrane Reviews: Four Proposals for Improvement. *J Palliat Med*, 2015. 18(11): p. 906-7.
 43. Currow, D.C., M. Ekstrom, and M.J. Johnson, Opioids in COPD: the whole picture using all available evidence. *Br J Clin Pharmacol*, 2015.
 44. Currow, D.C., et al., The Population Burden of Chronic Symptoms that Substantially Predate the Diagnosis of a Life-Limiting Illness. *J Palliat Med*, 2015. 18(6): p. 480-5.
 45. Currow, D.C., et al., Improving national hospice/palliative care service symptom outcomes systematically through point-of-care data collection, structured feedback and benchmarking. *Support Care Cancer*, 2015. 23(2): p. 307-15.
 46. Collier, A., et al., Academic detailing of general practitioners by a respiratory physician for diagnosis and management of refractory breathlessness: a randomised pilot study. *BMC Health Serv Res*, 2015. 15(1): p. 193.
 47. Clark, K., et al., Routine prescribing of gabapentin or pregabalin in supportive and palliative care: what are the comparative performances of the medications in a palliative care population? *Support Care Cancer*, 2015. 23(9): p. 2517-20.
 48. Clark, K. and D. Currow, Midazolam in palliative care: at what cost? *J Palliat Med*, 2015. 18(2): p. 96-7.
 49. Clark, K., A. Collier, and D.C. Currow, Dying in Australian hospitals: will a separate national clinical standard improve the delivery of quality care? *Aust Health Rev*, 2015. 39(2): p. 202-4.
 50. Ahmadi, Z., et al., End-of-life care in oxygen-dependent COPD and cancer: a national population-based study. *Eur Respir J*, 2015. 46(4): p. 1190-3.

2014

51. To, T.H., et al., Prescribing for nausea in palliative care: a cross-sectional national survey of

- Australian palliative medicine doctors. *J Palliat Med*, 2014. 17(9): p. 1032-6.
52. Sweet, L., et al., Ethical challenges and solutions regarding delirium studies in palliative care. *J Pain Symptom Manage*, 2014. 48(2): p. 259-71.
 53. Russell, B.J., D. Rowett, and D.C. Currow, Pro re nata prescribing in a population receiving palliative care: a prospective consecutive case note review. *J Am Geriatr Soc*, 2014. 62(9): p. 1736-40.
 54. Phillips, J.L., et al., Is the Life Space Assessment applicable to a palliative care population? Its relationship to measures of performance and quality of life. *J Pain Symptom Manage*, 2014. 47(6): p. 1121-7.
 55. McCaffrey, N., et al., Preliminary development and validation of a new end-of-life patient-reported outcome measure assessing the ability of patients to finalise their affairs at the end of life. *PLoS One*, 2014. 9(4): p. e94316.
 56. Leonard, M.M., et al., Practical assessment of delirium in palliative care. *J Pain Symptom Manage*, 2014. 48(2): p. 176-90.
 57. Lawlor, P.G., et al., An analytical framework for delirium research in palliative care settings: integrated epidemiologic, clinician-researcher, and knowledge user perspectives. *J Pain Symptom Manage*, 2014. 48(2): p. 159-75.
 58. Johnson, M.J., D. Hui, and D.C. Currow, Opioids, Exertion, and Dyspnea: A Review of the Evidence. *Am J Hosp Palliat Care*, 2014.
 59. Johnson, M.J., D.C. Currow, and S. Booth, Prevalence and assessment of breathlessness in the clinical setting. *Expert Rev Respir Med*, 2014. 8(2): p. 151-61.
 60. Johnson, M.J., et al., The relationship between two performance scales: New York Heart Association Classification and Karnofsky Performance Status Scale. *J Pain Symptom Manage*, 2014. 47(3): p. 652-8.
 61. Hardy, J.R., et al., Implementing practice change in chronic cancer pain management: clinician response to a phase III study of ketamine. *Intern Med J*, 2014. 44(6): p. 586-91.
 62. Ekstrom, M.P., et al., Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. *BMJ*, 2014. 348: p. g445.
 63. Disler, R.T., et al., Experience of advanced chronic obstructive pulmonary disease: metasynthesis of qualitative research. *J Pain Symptom Manage*, 2014. 48(6): p. 1182-99.
 64. Currow, D.C. and L.N. Sansom, Uptake of medicines and prescribing patterns in the palliative care schedule of the Pharmaceutical Benefits Scheme. *Med J Aust*, 2014. 200(10): p. 560-1.
 65. Currow, D.C., M. Ekstrom, and A.P. Abernethy, Opioids for chronic refractory breathlessness: right patient, right route? *Drugs*, 2014. 74(1): p. 1-6.
 66. Currow, D.C., A.P. Abernethy, and D.N. Ko, The active identification and management of chronic refractory breathlessness is a human right. *Thorax*, 2014. 69(4): p. 393-4.
 67. Currow, D.C. and A.P. Abernethy, The science of breathlessness: '... as we come onto the home straight, Science is catching Clinical Practice. Just two lengths between them'. *Curr Opin Support Palliat Care*, 2014. 8(3): p. 189-90.
 68. Currow, D.C. and A.P. Abernethy, Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. *Future Oncol*, 2014. 10(5): p. 789-802.
 69. Clark, K., et al., A prospective study to investigate contributory factors that lead to constipation in palliative care patients. *J Pain Symptom Manage*, 2014. 47(6): p. e1-4.
 70. Clark, K. and D.C. Currow, Methylalnaltrexone in palliative care: further research is needed. *J Pain Symptom Manage*, 2014. 47(2): p. e5-6.
 71. Clark, K. and D.C. Currow, Advancing research into symptoms of constipation at the end of life. *Int J Palliat Nurs*, 2014. 20(8): p. 370, 372.
 72. Bush, S.H., et al., End-of-life delirium: issues regarding recognition, optimal management, and the role of sedation in the dying phase. *J Pain Symptom Manage*, 2014. 48(2): p. 215-30.
 73. Bush, S.H., et al., Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development. *J*

Pain Symptom Manage, 2014. 48(2): p. 231-48.

74. Bush, S.H., et al., Clinical practice guidelines for delirium management: potential application in palliative care. *J Pain Symptom Manage*, 2014. 48(2): p. 249-58.

2013

75. To, T.H., et al., Off-label prescribing in palliative care - a cross-sectional national survey of palliative medicine doctors. *Palliat Med*, 2013. 27(4): p. 320-8.
76. To, T.H., M. Agar, and D.C. Currow, Rapid death after hospitalisation. *Intern Med J*, 2013. 43(4): p. 471.
77. Tait, P.A., et al., Community pharmacists: a forgotten resource for palliative care. *BMJ Support Palliat Care*, 2013. 3(4): p. 436-43.
78. Sanderson, C., et al., Placebo and nocebo effects in randomized controlled trials: the implications for research and practice. *J Pain Symptom Manage*, 2013. 46(5): p. 722-30.
79. Ritchie, C.S., et al., Multisite studies offer a solution to recruitment challenges in palliative care studies. *J Palliat Med*, 2013. 16(3): p. 225.
80. McConigley, R., T. Shelby-James, and D.C. Currow, Promoting the consumer voice in palliative care: exploring the possibility of using consumer impact statements. *Health Expect*, 2013.
81. McCaffrey, N., et al., Is home-based palliative care cost-effective? An economic evaluation of the Palliative Care Extended Packages at Home (PEACH) pilot. *BMJ Support Palliat Care*, 2013. 3(4): p. 431-5.
82. Johnson, M.J., A.P. Abernethy, and D.C. Currow, The evidence base for oxygen for chronic refractory breathlessness: issues, gaps, and a future work plan. *J Pain Symptom Manage*, 2013. 45(4): p. 763-75.
83. Hardy, J., et al., Reply to K. Jackson et al and W. Leppert. *J Clin Oncol*, 2013. 31(10): p. 1375-6.
84. Hardy, J., et al., Can the LANSS scale be used to classify pain in chronic cancer pain trials? *Support Care Cancer*, 2013. 21(12): p. 3387-91.
85. Currow, D.C., et al., The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea. *J Palliat Med*, 2013. 16(8): p. 881-6.
86. Currow, D.C., I.J. Higginson, and M.J. Johnson, Breathlessness--current and emerging mechanisms, measurement and management: a discussion from an European Association of Palliative Care workshop. *Palliat Med*, 2013. 27(10): p. 932-8.
87. Currow, D.C., M. Agar, and A.P. Abernethy, Hospital can be the actively chosen place for death. *J Clin Oncol*, 2013. 31(5): p. 651-2.
88. Currow, D.C. and A.P. Abernethy, Five years' time and the next five things for the list of choosing wisely. *J Palliat Med*, 2013. 16(6): p. 594-5.
89. Currow, D., et al., Evidence-based intervention for chronic refractory breathlessness: practical therapies that make a difference. *Br J Gen Pract*, 2013. 63(616): p. 609-10.
90. Crawford, G.B., et al., Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium. *J Palliat Med*, 2013. 16(11): p. 1335-41.
91. Clark, K., C. Sheehan, and D.C. Currow, Letter to the editor re "Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion". *J Palliat Med*, 2013. 16(7): p. 721-2.
92. Clark, K., et al., Uptake of methylnaltrexone in Australian patients with opioid-induced constipation: a review of the number of prescriptions presented in the first 12 months of subsidisation. *BMJ Support Palliat Care*, 2013. 3(1): p. 98-102.
93. Clark, K. and D.C. Currow, Constipation in palliative care: what do we use as definitions and outcome measures? *J Pain Symptom Manage*, 2013. 45(4): p. 753-62.
94. Clark, K. and D.C. Currow, A pilot study to assess the feasibility of measuring the prevalence of slow colon transit or evacuation disorder in palliative care. *J Palliat Med*, 2013. 16(5): p. 542-5.
95. Allcroft, P., et al., The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam. *J Palliat Med*, 2013. 16(7): p. 741-4.
96. Agar, M., et al., Informed consent in palliative care clinical trials: challenging but possible. *J*

Palliat Med, 2013. 16(5): p. 485-91.

97. Abernethy, A.P., et al., Delivery strategies to optimize resource utilization and performance status for patients with advanced life-limiting illness: results from the "palliative care trial" [ISRCTN 81117481]. *J Pain Symptom Manage*, 2013. 45(3): p. 488-505.

2012

98. To, T.H., et al., The disparity between patient and nurse symptom rating in a hospice population. *J Palliat Med*, 2012. 15(5): p. 542-7.
99. To, T.H., et al., The role of ondansetron in the management of cholestatic or uremic pruritus--a systematic review. *J Pain Symptom Manage*, 2012. 44(5): p. 725-30.
100. Shelby-James, T.M., et al., Designing and conducting randomized controlled trials in palliative care: A summary of discussions from the 2010 clinical research forum of the Australian Palliative Care Clinical Studies Collaborative. *Palliat Med*, 2012. 26(8): p. 1042-7.
101. Shelby-James, T.M., et al., Case conferences in palliative care - a substudy of a cluster randomised controlled trial. *Aust Fam Physician*, 2012. 41(8): p. 608-12.
102. Sheehan, C., M. Agar, and D.C. Currow, End-of-life research: do we need to build proxy consent into all clinical trial protocols studying the terminal phase? *J Palliat Med*, 2012. 15(9): p. 962.
103. Rowett, D.S., et al., Subsidised use of methylnaltrexone in Australia for palliative care. *Med J Aust*, 2012. 197(9): p. 492.
104. Le, B.H. and M.A. Rosenthal, Redefining the specialist palliative approach: clinical trials, a first year experience. *J Palliat Med*, 2012. 15(8): p. 846.
105. Johnson, M.J., A.P. Abernethy, and D.C. Currow, Gaps in the evidence base of opioids for refractory breathlessness. A future work plan? *J Pain Symptom Manage*, 2012. 43(3): p. 614-24.
106. Hardy, J., et al., Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. *J Clin Oncol*, 2012. 30(29): p. 3611-7.
107. Hardy, J. and D.C. Currow, Sector-wide approach to phase III studies. *Palliat Med*, 2012. 26(6): p. 864.
108. Currow, D.C., et al., Pharmacovigilance in hospice/palliative care: rapid report of net clinical effect of metoclopramide. *J Palliat Med*, 2012. 15(10): p. 1071-5.
109. Currow, D.C., et al., Refining a checklist for reporting patient populations and service characteristics in hospice and palliative care research. *J Pain Symptom Manage*, 2012. 43(5): p. 902-10.
110. Currow, D.C., O. Spruyt, and J. Hardy, Defining refractory pain in cancer for clinicians and researchers. *J Palliat Med*, 2012. 15(1): p. 5-6.
111. Currow, D.C., et al., An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. *J Palliat Med*, 2012. 15(3): p. 282-6.
112. Currow, D.C., et al., Analyzing phase III studies in hospice/palliative care. a solution that sits between intention-to-treat and per protocol analyses: the palliative-modified ITT analysis. *J Pain Symptom Manage*, 2012. 44(4): p. 595-603.
113. Currow, D.C., D.W. Bruner, and A.P. Abernethy, Editorial: death to the fiefdoms. *Curr Opin Support Palliat Care*, 2012. 6(4): p. 457-8.
114. Currow, D.C., A.P. Abernethy, and M.J. Johnson, Activity as a measure of symptom control. *J Pain Symptom Manage*, 2012. 44(5): p. e1-2.
115. Currow, D.C. and A.P. Abernethy, Breathlessness in an age of noncommunicable diseases. *Curr Opin Support Palliat Care*, 2012. 6(2): p. 127-8.
116. Clark, K., J.M. Smith, and D.C. Currow, The prevalence of bowel problems reported in a palliative care population. *J Pain Symptom Manage*, 2012. 43(6): p. 993-1000.
117. Clark, K., et al., Longitudinal pain reports in a palliative care population. *J Palliat Med*, 2012. 15(12): p. 1335-41.
118. Clark, K. and D.C. Currow, Assessing constipation in palliative care within a gastroenterology

framework. *Palliat Med*, 2012. 26(6): p. 834-41.

119. Clark, K. and D.C. Currow, Response to "A cross-sectional study of constipation and laxative use in advanced cancer patients: insights for revision of current practise". *Support Care Cancer*, 2012. 20(12): p. 3027-8; author reply 3031.
120. Clark, K. and D.C. Currow, Re: oral docusate in the management of constipation in hospice patients. *J Pain Symptom Manage*, 2012. 44(6): p. e6-7; author reply e8.
121. Clark, K., et al., Treating constipation in palliative care: the impact of other factors aside from opioids. *Am J Hosp Palliat Care*, 2012. 29(2): p. 122-5.
122. Agar, M., et al., Making decisions about delirium: a qualitative comparison of decision making between nurses working in palliative care, aged care, aged care psychiatry, and oncology. *Palliat Med*, 2012. 26(7): p. 887-96.
123. Abernethy, A.P. and D.C. Currow, Time-limited trials. *JAMA*, 2012. 307(1): p. 33-4; author reply 34.

2011

124. Uronis, H., et al., Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*, 2011(6): p. CD006429.
125. Lobb, E.A., et al., A collateral benefit of research in palliative care. *J Palliat Med*, 2011. 14(9): p. 986-7.
126. Hosie, A., et al., Palliative care clinical trials: how nurses are contributing to integrated, evidence-based care. *Int J Palliat Nurs*, 2011. 17(5): p. 224-30.
127. Hardy, J., M.R. Agar, and D.C. Currow, Progressing an evidence-base beyond case series. *J Palliat Med*, 2011. 14(12): p. 1283.
128. Currow, D.C., et al., Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. *J Pain Symptom Manage*, 2011. 42(3): p. 388-99.
129. Currow, D.C., et al., The need for a re-evaluation of best supportive care studies reported to date. *Br J Cancer*, 2011. 104(3): p. 390-1.
130. Currow, D.C., et al., Caregivers' perceived adequacy of support in end-stage lung disease: results of a population survey. *BMC Pulm Med*, 2011. 11: p. 55.
131. Currow, D.C., et al., Adverse events in hospice and palliative care: a pilot study to determine feasibility of collection and baseline rates. *J Palliat Med*, 2011. 14(3): p. 309-14.
132. Currow, D.C., et al., Measuring the net benefits of hospice and palliative care: a composite measure for multiple audiences-palliative net benefit. *J Palliat Med*, 2011. 14(3): p. 264-5.
133. Currow, D.C. and A.P. Abernethy, Therapeutic nihilism: the next hurdle in improving the treatment of breathlessness. *Curr Opin Support Palliat Care*, 2011. 5(2): p. 69-70.
134. Currow, D.C., The PRISMA Symposium 3: lessons from beyond Europe. why invest in research and service development in palliative care? An Australian perspective. *J Pain Symptom Manage*, 2011. 42(4): p. 505-10.
135. Clark, K., L. Lam, and D. Currow, Exploring the relationship between the frequency of documented bowel movements and prescribed laxatives in hospitalized palliative care patients. *Am J Hosp Palliat Care*, 2011. 28(4): p. 258-63.
136. Clark, K. and D.C. Currow, Plain abdominal radiographs to diagnose constipation patients with advanced progressive illness? *J Pain Symptom Manage*, 2011. 41(4): p. e2-3.
137. Abernethy, A.P. and D.C. Currow, Patient self-reporting in palliative care using information technology: Yes, there is hope! *Palliat Med*, 2011. 25(7): p. 673-4.

2010

138. Shelby-James, T., M.R. Agar, and D.C. Currow, A case study evaluation of ethics review systems for multicentre clinical trials. *Med J Aust*, 2010. 192(5): p. 292.
139. Horton, R., G. Rocker, and D. Currow, The dyspnea target: can we zero in on opioid responsiveness in advanced chronic obstructive pulmonary disease? *Curr Opin Support Palliat Care*, 2010. 4(2): p. 92-6.
140. Hardy, J., T. Shelby-James, and D.C. Currow, Research in palliative care: is death always an

- adverse event? *Intern Med J*, 2010. 40(1): p. 89-90.
141. Currow, D.C., et al., Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. *J Pain Symptom Manage*, 2010. 39(4): p. 680-90.
 142. Currow, D.C., et al., Planning phase III multi-site clinical trials in palliative care: the role of consecutive cohort audits to identify potential participant populations. *Support Care Cancer*, 2010. 18(12): p. 1571-9.
 143. Currow, D.C. and A.P. Abernethy, Potential opioid-sparing effect of regular benzodiazepines in dyspnea: longer duration of studies needed. *J Pain Symptom Manage*, 2010. 40(5): p. e1-2; author reply e2-4.
 144. Currow, D.C., Why don't we do more rigorous clinical research so that we can stop experimenting on patients? *J Palliat Med*, 2010. 13(6): p. 636-7.
 145. Currow, D. and M. Agar, The necessary work program for safe delivery of combinations of injectable medications. *J Palliat Med*, 2010. 13(9): p. 1052.
 146. Clark, K., K. Urban, and D.C. Currow, Current approaches to diagnosing and managing constipation in advanced cancer and palliative care. *J Palliat Med*, 2010. 13(4): p. 473-6.
 147. Clark, K., et al., The impact of opioids, anticholinergic medications and disease progression on the prescription of laxatives in hospitalized palliative care patients: a retrospective analysis. *Palliat Med*, 2010. 24(4): p. 410-8.
 148. Clark, K., D.C. Currow, and N.J. Talley, The use of digital rectal examinations in palliative care inpatients. *J Palliat Med*, 2010. 13(7): p. 797.
 149. Agar, M., et al., Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study. *J Palliat Med*, 2010. 13(6): p. 745-52.
 150. Abernethy, A.P., J.L. Wheeler, and D.C. Currow, Common approaches to dyspnoea management in advanced life-limiting illness. *Curr Opin Support Palliat Care*, 2010. 4(2): p. 53-5.
 151. Abernethy, A.P., et al., Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. *Lancet*, 2010. 376(9743): p. 784-93.
 152. Abernethy, A.P., et al., Enhancing enrollment in palliative care trials: key insights from a randomized, placebo-controlled study. *J Support Oncol*, 2010. 8(3): p. 139-44.
 153. Abernethy, A.P. and D.C. Currow, Need for mechanistically focused research of global systemic interventions in palliative care. *J Pain Symptom Manage*, 2010. 40(3): p. e5-8.
 154. Abernethy, A.P., K. Clark, and D.C. Currow, How should we conduct and interpret phase III clinical trials in palliative care? *J Pain Symptom Manage*, 2010. 39(1): p. e6-8.
 155. Abernethy, A.P., et al., A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. *J Palliat Med*, 2010. 13(12): p. 1407-13.

2009

156. Tieman, J.J., R.M. Sladek, and D.C. Currow, Multiple sources: mapping the literature of palliative care. *Palliat Med*, 2009. 23(5): p. 425-31.
157. Rowett, D., et al., Using national health policies to improve access to palliative care medications in the community. *J Pain Symptom Manage*, 2009. 37(3): p. 395-402.
158. McCaffrey, N., D.C. Currow, and S. Eckermann, Measuring impacts of value to patients is crucial when evaluating palliative care. *J Pain Symptom Manage*, 2009. 37(6): p. e7-9.
159. Currow, D.C., et al., A framework for generalizability in palliative care. *J Pain Symptom Manage*, 2009. 37(3): p. 373-86.
160. Currow, D.C., A.M. Ward, and A.P. Abernethy, Advances in the pharmacological management of breathlessness. *Curr Opin Support Palliat Care*, 2009. 3(2): p. 103-6.
161. Currow, D.C., et al., A community population survey of prevalence and severity of dyspnea in adults. *J Pain Symptom Manage*, 2009. 38(4): p. 533-45.
162. Currow, D.C., et al., Does palliative home oxygen improve dyspnoea? A consecutive cohort

study. *Palliat Med*, 2009. 23(4): p. 309-16.

163. Currow, D.C. and A.P. Abernethy, Ideas whose times have come. *Curr Opin Support Palliat Care*, 2009. 3(2): p. 91-2.
164. Currow, D.C., Even in death. *J Palliat Med*, 2009. 12(11): p. 983-4.
165. Clark, K., et al., The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. *Anaesthesia*, 2009. 64(6): p. 652-7.
166. Clark, K., L. Lam, and D. Currow, Reducing gastric secretions--a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction? *Support Care Cancer*, 2009. 17(12): p. 1463-8.
167. Agar, M., et al., Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. *Palliat Med*, 2009. 23(3): p. 257-65.
168. Abernethy, A.P., et al., Management of dyspnea in patients with chronic obstructive pulmonary disease. *Wien Med Wochenschr*, 2009. 159(23-24): p. 583-90.

2008

169. Currow, D.C., et al., Caregivers for people with end-stage lung disease: characteristics and unmet needs in the whole population. *Int J Chron Obstruct Pulmon Dis*, 2008. 3(4): p. 753-62.
170. Currow, D.C., et al., Is it feasible and desirable to collect voluntarily quality and outcome data nationally in palliative oncology care? *J Clin Oncol*, 2008. 26(23): p. 3853-9.
171. Currow, D.C., et al., Do terminally ill people who live alone miss out on home oxygen treatment? An hypothesis generating study. *J Palliat Med*, 2008. 11(7): p. 1015-22.
172. Currow, D.C., et al., Multi-site research allows adequately powered palliative care trials; web-based data management makes it achievable today. *Palliat Med*, 2008. 22(1): p. 91-2.
173. Currow, D.C., Managing respiratory symptoms in everyday practice. *Curr Opin Support Palliat Care*, 2008. 2(2): p. 81-3.
174. Cranston, J.M., A. Crockett, and D. Currow, Oxygen therapy for dyspnoea in adults. *Cochrane Database Syst Rev*, 2008(3): p. CD004769.
175. Clark, K., et al., A pilot phase II randomized, cross-over, double-blinded, controlled efficacy study of octreotide versus hyoscine hydrobromide for control of noisy breathing at the end-of-life. *J Pain Palliat Care Pharmacother*, 2008. 22(2): p. 131-8.
176. Agar, M., et al., Differing management of people with advanced cancer and delirium by four sub-specialties. *Palliat Med*, 2008. 22(5): p. 633-40.
177. Abernethy, A.P. and D.C. Currow, Culture and financing influence palliative care services, study populations, and generalizability of research findings. *J Palliat Med*, 2008. 11(2): p. 146.

2007

178. Stevenson, J.P., D.C. Currow, and A.P. Abernethy, Frameworks for prescribing in comorbid illness. *J Pain Symptom Manage*, 2007. 34(2): p. 117-8.
179. Stevenson, J.P., D.C. Currow, and A.P. Abernethy, The broader implications of managing statins at the end of life. *J Palliat Care*, 2007. 23(3): p. 188-9; author reply 189.
180. Shelby-James, T.M., et al., Promoting patient centred palliative care through case conferencing. *Aust Fam Physician*, 2007. 36(11): p. 961-4.
181. Shelby-James, T.M., et al., Handheld computers for data entry: high tech has its problems too. *Trials*, 2007. 8: p. 5.
182. Currow, D.C., et al., Prescribing in palliative care as death approaches. *J Am Geriatr Soc*, 2007. 55(4): p. 590-5.
183. Currow, D.C., et al., A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer. *J Pain Symptom Manage*, 2007. 34(1): p. 17-23.
184. Currow, D.C., et al., Can we predict which patients with refractory dyspnea will respond to opioids? *J Palliat Med*, 2007. 10(5): p. 1031-6.
185. Currow, D.C., B. Fazekas, and A.P. Abernethy, Oxygen use--patients define symptomatic benefit discerningly. *J Pain Symptom Manage*, 2007. 34(2): p. 113-4.

186. Currow, D.C. and A.P. Abernethy, Pharmacological management of dyspnoea. *Curr Opin Support Palliat Care*, 2007. 1(2): p. 96-101.

2006

187. Uronis, H.E., D.C. Currow, and A.P. Abernethy, Palliative management of refractory dyspnea in COPD. *Int J Chron Obstruct Pulmon Dis*, 2006. 1(3): p. 289-304.

188. Shelby-James, T., A.P. Abernethy, and D.C. Currow, Evidence in palliative care research: how should it be gathered? *Med J Aust*, 2006. 184(4): p. 196-7.

189. Good, P.D., et al., What are the essential medications in palliative care? - a survey of Australian palliative care doctors. *Aust Fam Physician*, 2006. 35(4): p. 261-4.

190. Currow, D.C., et al., The impact of conducting a regional palliative care clinical study. *Palliat Med*, 2006. 20(8): p. 735-43.

191. Currow, D.C. and A.P. Abernethy, Reader questions benefit of nebulized opioids. *Oncol Nurs Forum*, 2006. 33(3): p. 513; author reply 513-4.

192. Currow, D.C. and A.P. Abernethy, Frameworks for approaching prescribing at the end of life. *Arch Intern Med*, 2006. 166(21): p. 2404.